Clinical Heterogeneity in ME/CFS. A Way to Understand Long-COVID19 Fatigue.

Chronic Fatigue Syndrome Myalgic Encephalomyelitis dysautonomia long COVID-19 post-viral fatigue

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2021
Historique:
received: 05 07 2021
accepted: 13 09 2021
entrez: 28 10 2021
pubmed: 29 10 2021
medline: 29 10 2021
Statut: epublish

Résumé

The aim of present paper is to identify clinical phenotypes in a cohort of patients affected of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Ninety-one patients and 22 healthy controls were studied with the following questionnaires, in addition to medical history: visual analogical scale for fatigue and pain, DePaul questionnaire (post-exertional malaise, immune, neuroendocrine), Pittsburgh sleep quality index, COMPASS-31 (dysautonomia), Montreal cognitive assessment, Toulouse-Piéron test (attention), Hospital Anxiety and Depression test and Karnofsky scale. Co-morbidities and drugs-intake were also recorded. A hierarchical clustering with clinical results was performed. Final study group was made up of 84 patients, mean age 44.41 ± 9.37 years (66 female/18 male) and 22 controls, mean age 45 ± 13.15 years (14 female/8 male). Patients meet diagnostic criteria of Fukuda-1994 and Carruthers-2011. Clustering analysis identify five phenotypes. Two groups without fibromyalgia were differentiated by various levels of anxiety and depression (13 and 20 patients). The other three groups present fibromyalgia plus a patient without it, but with high scores in pain scale, they were segregated by prevalence of dysautonomia (17), neuroendocrine (15), and immunological affectation (19). Regarding gender, women showed higher scores than men in cognition, pain level and depressive syndrome. Mathematical tools are a suitable approach to objectify some elusive features in order to understand the syndrome. Clustering unveils phenotypes combining fibromyalgia with varying degrees of dysautonomia, neuroendocrine or immune features and absence of fibromyalgia with high or low levels of anxiety-depression. There is no a specific phenotype for women or men.

Identifiants

pubmed: 34707521
doi: 10.3389/fpsyt.2021.735784
pmc: PMC8542754
doi:

Types de publication

Journal Article

Langues

eng

Pagination

735784

Informations de copyright

Copyright © 2021 Murga, Aranburu, Gargiulo, Gómez Esteban and Lafuente.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Clin Psychol. 2012 Jan;68(1):41-9
pubmed: 21823124
Brain Nerve. 2018 Jan;70(1):19-25
pubmed: 29348371
Neurosci Med. 2011 Mar 1;2(1):14-27
pubmed: 21892413
Viruses. 2019 Dec 20;12(1):
pubmed: 31861926
Front Microbiol. 2021 Jun 23;12:698169
pubmed: 34248921
Mol Psychiatry. 2016 Apr;21(4):450-63
pubmed: 26878891
Ann Intern Med. 1994 Dec 15;121(12):953-9
pubmed: 7978722
Front Behav Neurosci. 2019 Apr 05;13:68
pubmed: 31024271
J Biosens Biomark Diagn. 2017;2(1):
pubmed: 29204592
Psychol Med. 2010 Aug;40(8):1253-67
pubmed: 20047703
J Intern Med. 2011 Oct;270(4):327-38
pubmed: 21777306
J Transl Med. 2018 Oct 1;16(1):268
pubmed: 30285773
Curr Neuropharmacol. 2015;13(5):701-34
pubmed: 26411464
Psychol Psychother. 2017 Sep;90(3):502-509
pubmed: 28244209
Postgrad Med J. 1978 Nov;54(637):711-7
pubmed: 370810
Gen Psychiatr. 2019 Dec 18;32(6):e100137
pubmed: 31922088
Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5472-80
pubmed: 27573827
Am J Psychiatry. 2003 Feb;160(2):221-36
pubmed: 12562565
PLoS One. 2019 Mar 25;14(3):e0213724
pubmed: 30908516
N Engl J Med. 2021 Aug 12;385(7):577-579
pubmed: 34192429
Medicina (Kaunas). 2021 Apr 26;57(5):
pubmed: 33925784
J Clin Psychopharmacol. 2011 Aug;31(4):403-5
pubmed: 21694612
Curr Rheumatol Rep. 2016 May;18(5):24
pubmed: 27032787
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Eur J Clin Invest. 2014 May;44(5):516-26
pubmed: 24601948
Front Pediatr. 2019 Feb 05;7:12
pubmed: 30805319
Diagnostics (Basel). 2018 Sep 11;8(3):
pubmed: 30208578
Aten Primaria. 2019 Nov;51(9):579-585
pubmed: 31182238
Lancet. 2006 Jan 28;367(9507):346-55
pubmed: 16443043
Dyn Med. 2008 Apr 08;7:6
pubmed: 18397528
Clin Med (Lond). 2021 Jan;21(1):e63-e67
pubmed: 33243837
PLoS One. 2020 Apr 30;15(4):e0232475
pubmed: 32353033
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
J Intern Med. 2013 May;273(5):501-10
pubmed: 23206180
Pediatric Health Med Ther. 2018 Mar 29;9:27-33
pubmed: 29722371

Auteurs

Iñigo Murga (I)

LaNCE-Neuropharm Group, Department of Neuroscience, University of the Basque Country (UPV-EHU), Leioa, Spain.

Larraitz Aranburu (L)

Department of Mathematics, University of the Basque Country (UPV-EHU), Leioa, Spain.

Pascual A Gargiulo (PA)

Lab Experimental Psychology, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Department of Pathology, Universidad Nacional de Cuyo (UNC), Mendoza, Argentina.

Juan Carlos Gómez Esteban (JC)

LaNCE-Neuropharm Group, Department of Neuroscience, University of the Basque Country (UPV-EHU), Leioa, Spain.
Neurodegenerative Disease Group, Biocruces Research Institute, Barakaldo, Spain.

José-Vicente Lafuente (JV)

LaNCE-Neuropharm Group, Department of Neuroscience, University of the Basque Country (UPV-EHU), Leioa, Spain.
Neurodegenerative Disease Group, Biocruces Research Institute, Barakaldo, Spain.

Classifications MeSH